CA Patent

CA2624380A1 — Method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding

Assigned to Bayer Pharma AG · Expires 2007-04-19 · 19y expired

What this patent protects

The invention relates to a method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding, where an oral monophasic combination of dienogest and ethinylestradiol in low dosage is used together with one or more pharmaceutically acce…

USPTO Abstract

The invention relates to a method for manufacturing a monophasic pharmaceutical product for oral therapy of dysfunctional uterine bleeding, where an oral monophasic combination of dienogest and ethinylestradiol in low dosage is used together with one or more pharmaceutically acceptable excipients/carriers, with which moderate proliferation of the endometrium with complete transformation and brief and slight withdrawal bleeding in the hormone-free period is achieved through the hormone levels remaining at a constant low level.

Drugs covered by this patent

Patent Metadata

Patent number
CA2624380A1
Jurisdiction
CA
Classification
—
Expires
2007-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.